FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Wednesday

 

MS Society Funds 3 New Investigations into Symptom Management



























Projects looking at clinical trials, fatigue and urinary infections share £1.98 million award

The Multiple Sclerosis Society (MS Society) in the U.K. recently announced  awards targeted towards new MS research. In total, 16 projects carefully selected by both a panel of experts and patients living with MS will share MS Society 2015 funding grants amounting to £1,979,879.

All projects fulfilled the requirements of high scientific quality, sound evidence base and alignment with the MS Society’s research strategy; moreover, they were considered relevant by MS patients themselves. The projects were grouped into four topics: cause, cure, care and services, and symptom management.

Three projects were selected within the category of MS symptom management. The first, led by Professor Avril Drummond from the University of Nottingham, will receive £64,655. The study is entitled “Helping people manage cognitive problems: translating research into practice” and its goal is to ensure that the results of clinical trials are properly and effectively translated into clinical practice. The research focuses on the ongoing CRAMMS trial, the largest symptom-management trial in the U.K., which is evaluating whether group-based cognitive rehabilitation can help improve memory and attention in MS patients, two relevant cognitive symptoms in this population. The team will conduct a side study of CRAMMS to assess the impact that the trial has in clinic settings, and to determine ways to improve the link between trials and clinical practice, and the number of MS patients who might benefit from a trial’s findings.

The second project, titled “Can a flavonoid-rich cocoa drink improve fatigue?” and led by Professor Helen Dawes from Oxford Brookes University, will receive £69,991. The goal of the project is to determine whether a flavonoid-rich cocoa drink can help ease fatigue in MS patients. Flavonoids are thought to have anti-inflammatory properties and to be able to prevent the damage caused by harmful free radicals. The team will investigate whether the intake of a flavonoid-rich cocoa drink has a beneficial effect in terms of fatigue, inflammation, and free radical damage in patients with MS.

The third project, awarded £29,148, is led by Dr. Jennifer Rohn from the University College London and titled “Understanding urinary tract infections in MS using a model bladder.” Urinary tract infection (UTI) is a common complication in MS patients, and although long-term antibiotic treatment can ease bladder symptoms and improve the patient’s quality of life, such long-term use can carry serious side effects. Alternative treatments are required. The goal of the project is to develop an innovative model bladder that allows the identification of genes involved in chronic UTI, and to find possible new therapeutic targets for this condition.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length

Labels: ,



Go to Newer News Go to Older News